canada clinical guidance

Chlamydia (uncomplicated genital infection)

A Canadian clinical summary of chlamydia (uncomplicated genital infection), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Chlamydia and LGV guide: Treatment and follow-up. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:PHAC chlamydia

Source-attributed clinical priorities

  • Use nucleic-acid testing from exposed anatomic sites and assess pregnancy and symptoms of upper-genital or epididymal infection.
  • Treat with the current PHAC regimen and account for pregnancy, adherence and possible lymphogranuloma venereum.
  • Arrange partner management, abstinence advice, retesting and other STI screening under local public-health requirements.
  • Test all exposed sites and treat partners to prevent reinfection.
sources for this section:PHAC chlamydia

Practical assessment and management workflow

1
Ask about anatomic exposure, symptoms, pregnancy, allergy and prior infection.
2
Collect nucleic-acid testing and offer gonorrhea, syphilis and HIV testing as appropriate.
3
Give the current Canadian regimen and communicate abstinence advice until treatment is complete.
4
Arrange partner notification and repeat testing at the recommended interval.
sources for this section:PHAC chlamydia

Safety, red flags and urgent escalation

  • Pelvic pain, testicular pain, fever or pregnancy requires complication-aware management.
  • Use a pregnancy-compatible regimen and arrange follow-up when indicated.
  • Do not use a test of cure too early because residual nucleic acid can remain detectable.
sources for this section:PHAC chlamydia

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:PHAC chlamydia

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:PHAC chlamydia

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Public Health Agency of CanadaChlamydia and LGV guide: Treatment and follow-upaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.